Nisa Investment Advisors LLC decreased its holdings in Amedisys Inc (NASDAQ:AMED) by 1.2% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 15,240 shares of the health services provider’s stock after selling 180 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Amedisys were worth $3,026,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of AMED. FMR LLC increased its holdings in Amedisys by 13.4% during the 1st quarter. FMR LLC now owns 370,789 shares of the health services provider’s stock worth $45,703,000 after purchasing an additional 43,844 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. grew its position in Amedisys by 18.8% during the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,828 shares of the health services provider’s stock valued at $444,000 after buying an additional 448 shares during the period. Geode Capital Management LLC increased its holdings in Amedisys by 3.9% during the fourth quarter. Geode Capital Management LLC now owns 469,777 shares of the health services provider’s stock worth $78,415,000 after buying an additional 17,435 shares during the last quarter. Sunbelt Securities Inc. bought a new stake in Amedisys in the fourth quarter worth about $9,222,000. Finally, Macquarie Group Ltd. boosted its stake in Amedisys by 64.7% in the fourth quarter. Macquarie Group Ltd. now owns 24,386 shares of the health services provider’s stock valued at $4,070,000 after acquiring an additional 9,582 shares during the last quarter. 88.31% of the stock is owned by hedge funds and other institutional investors.
NASDAQ AMED opened at $234.16 on Friday. The company’s 50 day simple moving average is $202.10 and its two-hundred day simple moving average is $187.33. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.02 and a quick ratio of 1.48. Amedisys Inc has a 1 year low of $121.00 and a 1 year high of $237.28. The stock has a market capitalization of $7.59 billion, a PE ratio of 52.32, a P/E/G ratio of 3.44 and a beta of 0.95.
Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Tuesday, July 28th. The health services provider reported $1.34 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.53. The firm had revenue of $485.06 million for the quarter, compared to analysts’ expectations of $468.38 million. Amedisys had a net margin of 6.50% and a return on equity of 22.41%. The business’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.21 earnings per share. On average, research analysts anticipate that Amedisys Inc will post 4.82 EPS for the current year.
In other news, insider Sharon Brunecz sold 2,185 shares of the stock in a transaction on Friday, June 19th. The shares were sold at an average price of $196.00, for a total value of $428,260.00. Following the transaction, the insider now owns 23,327 shares of the company’s stock, valued at approximately $4,572,092. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Denise M. Bohnert sold 362 shares of the firm’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $220.00, for a total transaction of $79,640.00. Following the sale, the insider now owns 9,095 shares in the company, valued at approximately $2,000,900. The disclosure for this sale can be found here. In the last ninety days, insiders sold 38,693 shares of company stock worth $6,882,126. Insiders own 2.90% of the company’s stock.
A number of research firms recently commented on AMED. Zacks Investment Research raised shares of Amedisys from a “hold” rating to a “buy” rating and set a $193.00 price target on the stock in a report on Friday, May 1st. Oppenheimer reaffirmed a “buy” rating and set a $215.00 price target on shares of Amedisys in a research report on Monday, April 27th. BidaskClub raised Amedisys from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Royal Bank of Canada boosted their price objective on Amedisys from $218.00 to $260.00 and gave the company an “outperform” rating in a research note on Thursday. Finally, Benchmark increased their target price on shares of Amedisys from $210.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday. Five investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $215.67.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
Read More: What Factors Can Affect Return on Equity?
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.